GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SSY Group Ltd (HKSE:02005) » Definitions » EV-to-Revenue

SSY Group (HKSE:02005) EV-to-Revenue : 2.43 (As of May. 21, 2024)


View and export this data going back to 2005. Start your Free Trial

What is SSY Group EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, SSY Group's enterprise value is HK$15,713 Mil. SSY Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$6,463 Mil. Therefore, SSY Group's EV-to-Revenue for today is 2.43.

The historical rank and industry rank for SSY Group's EV-to-Revenue or its related term are showing as below:

HKSE:02005' s EV-to-Revenue Range Over the Past 10 Years
Min: 2   Med: 3.91   Max: 9.17
Current: 2.43

During the past 13 years, the highest EV-to-Revenue of SSY Group was 9.17. The lowest was 2.00. And the median was 3.91.

HKSE:02005's EV-to-Revenue is ranked worse than
51.8% of 1025 companies
in the Drug Manufacturers industry
Industry Median: 2.41 vs HKSE:02005: 2.43

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-21), SSY Group's stock price is HK$4.71. SSY Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2.17. Therefore, SSY Group's PS Ratio for today is 2.17.


SSY Group EV-to-Revenue Historical Data

The historical data trend for SSY Group's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SSY Group EV-to-Revenue Chart

SSY Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.36 3.42 2.57 2.28 2.59

SSY Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.57 - 2.28 - 2.59

Competitive Comparison of SSY Group's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SSY Group's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SSY Group's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where SSY Group's EV-to-Revenue falls into.



SSY Group EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

SSY Group's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=15713.384/6463.009
=2.43

SSY Group's current Enterprise Value is HK$15,713 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SSY Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$6,463 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SSY Group  (HKSE:02005) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

SSY Group's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=4.71/2.17
=2.17

SSY Group's share price for today is HK$4.71.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$2.17.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SSY Group EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of SSY Group's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


SSY Group (HKSE:02005) Business Description

Traded in Other Exchanges
N/A
Address
Central Plaza, 18 Harbour Road, Rooms 4902-03, 49th Floor, Wanchai, Hong Kong, HKG
SSY Group Ltd is engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, which includes finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The company has two reportable segments including intravenous infusion solution and others and medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.

SSY Group (HKSE:02005) Headlines

No Headlines